A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.
Latest Information Update: 15 Jul 2019
At a glance
- Drugs ICX-RHY (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- Sponsors Intercytex
Most Recent Events
- 14 Jul 2019 Status changed from recruiting to completed.
- 03 Nov 2014 New trial record